文献速递乳腺癌放疗

HER-2阳性乳腺癌原发全身治疗与乳房切除术后放疗:TRYPHAENA与NeoSphere试验的汇总分析

Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials.
PubMed 文献 · Radiother Oncol · 2023-04-06

该研究汇总TRYPHAENA与NeoSphere两项随机II期试验中312例淋巴结阳性HER-2阳性乳腺癌患者,评估原发全身治疗后根据病理反应决定是否行乳房切除术后放疗(PMRT)的疗效。达到淋巴结病理完全缓解(ypN0)者5年局部区域无复发生存率在PMRT组与未PMRT组均为97%(p=0.94);ypN2-3患者接受PMRT者5年LRRFS为92%,未接受者为75%(p=0.019)。结论支持ypN0患者降级PMRT,而ypN2-3患者从PMRT中获得显著获益。

要点

  • 312例淋巴结阳性HER-2阳性乳腺癌患者中,172例(55%)达到ypN0,140例(45%)未达到。
  • ypN0患者5年LRRFS在PMRT组与未PMRT组均为97%(p=0.94)。
  • ypN2-3患者接受PMRT者5年LRRFS为92%,未接受者为75%(p=0.019)。

核心结论

  • HER-2阳性乳腺癌患者原发全身治疗后达到ypN0者局部区域控制良好,支持降级PMRT。
  • ypN2-3患者从PMRT中获得显著获益。
  • 初诊临床淋巴结分期与ypN0状态与局部区域复发风险显著相关。

研究设计与样本

  • TRYPHAENA与NeoSphere均为随机II期试验,研究HER-2阳性乳腺癌的原发全身治疗。
  • 本研究为两项试验的汇总分析,纳入312例接受HER-2靶向原发全身治疗后行乳房切除术(联合或不联合PMRT)的淋巴结阳性患者。
  • 主要终点为局部区域无复发生存率(LRRFS)。

主要发现

  • 172例(55%)达到淋巴结病理完全缓解(ypN0),140例(45%)未达到。
  • ypN0患者PMRT组与未PMRT组的5年LRRFS均为97%(p=0.94)。
  • ypN+患者PMRT组5年LRRFS为89%,未PMRT组为82%(p=0.17)。
  • ypN1患者(n=62)中,接受PMRT者(n=40)5年LRRFS为85%,未接受者(n=22)为89%(p=0.60)。
  • ypN2-3患者(n=78)中,接受PMRT者(n=53)5年LRRFS为92%,未接受者(n=25)为75%(p=0.019)。

关键数值与推荐

  • ypN0患者5年LRRFS:PMRT组97% vs 未PMRT组97%(p=0.94)。
  • ypN+患者5年LRRFS:PMRT组89% vs 未PMRT组82%(p=0.17)。
  • ypN1患者5年LRRFS:PMRT组85%(n=40) vs 未PMRT组89%(n=22)(p=0.60)。
  • ypN2-3患者5年LRRFS:PMRT组92%(n=53) vs 未PMRT组75%(n=25)(p=0.019)。

临床怎么用

  • HER-2阳性乳腺癌患者原发全身治疗后达到ypN0者局部区域控制良好,作者结论支持降级PMRT。
  • ypN2-3患者从PMRT中获得显著获益。
  • 初诊临床淋巴结分期与ypN0状态与局部区域复发风险显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of post-mastectomy radiation therapy (PMRT) following primary systemic therapy (PST) in HER-2 positive breast cancer (Her2 + BC) remains poorly understood. The current study evaluates PMRT based on the pathological response to PST in Her2 + BC. METHODS AND MATERIALS: TRYPHAENA and NeoSphere are randomized phase II trials that investigated PST for Her2 + BC. Our study is a pooled analysis of both trials, including 312 node-positive patients treated with HER-2 targeted PST followed by mastectomy with or without PMRT. The primary endpoint is loco-regional recurrence-free survival (LRRFS). RESULTS: Our analysis included 172 (55%) patients who achieved complete nodal pathological response (ypN0) and 140 (45%) patients who did not. Patients with ypN0 had a 5-year LRRFS of 97% in both, the PMRT and no PMRT, groups (p = 0.94). Patients with ypN + had 5-year LRRFS of 89% in the PMRT group and 82% in the no PMRT group (p = 0.17). Patients with ypN1 (n = 62) disease who received PMRT (n = 40) had a 5-year LRRFS of 85% as compared to 89% in those who did not (n = 22); (p = 0.60). A significant LRRFS difference was noted in patients with ypN2-3 (n = 78) disease who received PMRT (n = 53) compared to those who did not (n = 25) (5-year LRRFS 92% vs. 75%; p = 0.019). On multivariate analysis, clinical nodal disease at diagnosis and ypN0 were significantly associated with loco-regional recurrence (LRR). CONCLUSIONS: Her2 + BC patients who achieve ypN0 after PST have excellent locoregional-control which supports de-escalation of PMRT. In contrast, patients with ypN2-3 disease derive significant benefit from PMRT. Clinical nodal stage at presentation and ypN0 status are significantly associated with LRR risk in Her2 + BC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Saifi O, Bachir B, Panoff J, et al. Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. Radiother Oncol. 2023. PMID: 37030399. doi:10.1016/j.radonc.2023.109668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。